IB. AMENDMENTS TO THE CLAIMS

Cancel claims 1-29 without prejudice to renewal.

Please enter new claims 30-41, as shown below.

1.-29. (Cancelled)

30. (**New**) A vaccine comprising:

a) a recombinant Modified Vaccinia Vaccine Ankara (MVA) virus comprising a nucleotide sequence encoding *Plasmodium falciparum* merozoite surface protein-1 (MSP-1) fragments, wherein the MSP-1 fragments are:

i) p42 and p38; or

ii) p83, p30, p42, and p38; and

b) a pharmacologically compatible carrier,

wherein the vaccine does not comprise an adjuvant.

31. (**New**) The vaccine of claim 30, further comprising MSP-1 protein, or a fragment thereof.

32. (**New**) The vaccine of claim 30, wherein the nucleotide sequence encoding the MSP-1 fragments is under the control of a promoter.

33. (**New**) The vaccine of claim 30, wherein the nucleotide sequence encoding the MSP-1 fragments comprises at its 5' end a nucleotide sequence encoding a signal peptide sequence.

34. (**New**) The vaccine of claim 33, wherein the signal peptide sequence controls secretion, localization, or glycosylphosphatidylinositol anchoring of the MSP-1 fragments.

35. (**New**) A method for therapy of malaria, the method comprising administering the vaccine of claim 30.

36. (**New**) The method of claim 35, wherein the method does not comprise administering a DNA prime or a DNA booster.

37. (**New**) A vaccine kit comprising:

a) a recombinant Modified Vaccinia Vaccine Ankara (MVA) virus comprising a nucleotide sequence encoding *Plasmodium falciparum* merozoite surface protein-1 (MSP-1) fragments, wherein the MSP-1 fragments are:

i) p42 and p38; or

ii) p83, p30, p42, and p38; and; and

b) a pharmacologically acceptable carrier.

38. (**New**) The kit of claim 37, further comprising:

c) MSP-1 protein, or a fragment thereof.

39. (**New**) The kit of claim 37, wherein components (a) and (c) are suitable for simultaneous, sequential or separate administration.

40. (**New**) A recombinant Modified Vaccinia Vaccine Ankara (MVA) virus comprising a nucleotide sequence encoding *Plasmodium falciparum* merozoite surface protein-1 (MSP-1) fragments, wherein the MSP-1 fragments are p42 and p38 fragments.

41. (**New**) A recombinant Modified Vaccinia Vaccine Ankara (MVA) virus comprising at least one nucleic acid encoding *Plasmodium falciparum* merozoite surface protein-1 (MSP-1) fragments, wherein the MSP-1 fragments are p83, p30, p42, and p38 fragments.